Neurocrine Biosciences Updates on CRENESSITY (Crinecerfont) Reaching $750 Million Quarterly Run Rate 12 Months Post-Approval at Wells Fargo Healthcare Conference Wednesday
Neurocrine Biosciences (NASDAQ: NBIX) hosted a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston Wednesday September 9, 2026 at 12:45 p.m. ET, disclosing that CRENESSITY (crinecerfont, a first-in-class oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist for classic congenital adrenal hyperplasia (CAH)) has reached approximately $750 million in quarterly run-rate revenue approximately 12 months after its FDA approval in December 2024 for pediatric patients aged 4 and older and adults with CAH. The company posted its first billion-dollar quarter in Q2 2026 and moved from a single-product company (Ingrezza for tardive dyskinesia) to three commercial products, with underlying Ingrezza volume growth of 17% and 2026 guidance at the $2.85 billion midpoint. CRF is a peptide hormone, and CRENESSITY blocks the CRF1 receptor to reduce excess ACTH secretion and androgen production in CAH — the mechanism replaces high-dose glucocorticoid therapy for many patients. Neurocrine reported zero debt and approximately $500 million in cash.